BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers

INTRODUCTION: Intrinsic or acquired chemoresistance is a major problem in oncology. Although highly responsive to chemotherapies such as paclitaxel, most triple negative breast cancer (TNBC) patients develop chemoresistance. Here we investigate the role of BRCA1-IRIS as a novel treatment target for...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanchard, Zannel, Paul, Bibbin T, Craft, Barbara, ElShamy, Wael M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322455/
https://www.ncbi.nlm.nih.gov/pubmed/25583261
http://dx.doi.org/10.1186/s13058-014-0512-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322455/
https://www.ncbi.nlm.nih.gov/pubmed/25583261
http://dx.doi.org/10.1186/s13058-014-0512-9

Ejemplares similares